Certara (NASDAQ:CERT) PT Lowered to $16.00 at Barclays

Certara (NASDAQ:CERT) had its price objective lowered by Barclays from $18.00 to $16.00 in a research note released on Friday morning, Benzinga reports. The firm currently has an equal weight rating on the stock.

Other analysts also recently issued reports about the company. KeyCorp upgraded Certara from a sector weight rating to an overweight rating and set a $23.00 price objective on the stock in a research report on Wednesday, April 10th. JMP Securities began coverage on Certara in a report on Thursday, April 4th. They issued a market perform rating for the company. Jefferies Financial Group increased their price target on Certara from $14.00 to $15.50 and gave the company a hold rating in a report on Friday, March 1st. Finally, UBS Group increased their price target on Certara from $17.00 to $20.00 and gave the company a neutral rating in a report on Friday, March 1st. Seven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Certara currently has an average rating of Hold and a consensus price target of $19.81.

Certara Stock Performance

Shares of Certara stock opened at $13.85 on Friday. The business has a 50-day moving average of $16.03 and a 200 day moving average of $16.88. Certara has a 12 month low of $11.81 and a 12 month high of $19.87. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -35.51, a price-to-earnings-growth ratio of 4.65 and a beta of 1.58. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.26 and a quick ratio of 3.26.

Certara (NASDAQ:CERT) last issued its earnings results on Tuesday, May 7th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. The business had revenue of $96.65 million for the quarter, compared to analyst estimates of $94.48 million. As a group, sell-side analysts forecast that Certara will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other Certara news, insider Patrick F. Smith sold 14,427 shares of Certara stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total transaction of $243,094.95. Following the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at $844,033.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.39% of the stock is owned by company insiders.

Institutional Trading of Certara

Several institutional investors and hedge funds have recently made changes to their positions in CERT. Charles Schwab Investment Management Inc. boosted its stake in shares of Certara by 5.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 607,030 shares of the company’s stock worth $8,826,000 after buying an additional 32,790 shares during the last quarter. HighTower Advisors LLC raised its holdings in shares of Certara by 24.8% in the 3rd quarter. HighTower Advisors LLC now owns 27,500 shares of the company’s stock valued at $390,000 after purchasing an additional 5,467 shares during the period. Envestnet Asset Management Inc. raised its holdings in Certara by 45.3% in the 3rd quarter. Envestnet Asset Management Inc. now owns 335,440 shares of the company’s stock valued at $4,877,000 after acquiring an additional 104,616 shares during the period. Natixis Advisors L.P. raised its holdings in Certara by 13.4% in the 3rd quarter. Natixis Advisors L.P. now owns 15,136 shares of the company’s stock valued at $220,000 after acquiring an additional 1,791 shares during the period. Finally, Trexquant Investment LP raised its holdings in Certara by 154.2% in the 3rd quarter. Trexquant Investment LP now owns 46,216 shares of the company’s stock valued at $672,000 after acquiring an additional 28,032 shares during the period. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.